Member Directory

Primary tabs

Chair: Charles Flexner

Objectives:

Create the scientific and programmatic agenda of LEAP to ensure a balanced and objective resource for those engaged in developing LA/ER agents for treatment and prevention of HIV, TB, and Hepatitis B & C.
Bring a broad representation including academic experts in LA/ER therapeutic drug development, community representatives, and non-governmental organizations (NGO’s) with an interest in supporting this field.
Serve as an honest broker to bridge gaps between academia, regulatory agencies, the pharmaceutical industry, and the community.

Charles W. Flexner, MD flex@jhmi.edu Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Receives consulting fees from Gilead Sciences, Merck, Janssen, ViiV Healthcare. Has an ownership interest in Navigen LLC, and receives grant funding from Gilead Sciences.	Elaine J. Abrams, MD eja1@columbia.edu Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Robert Bollinger, MD, MPH rcb@jhmi.edu Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. Conflict of Interest: Receives royalties from emocha Health, miDiagnostics, consulting fees from Merck, Hologic, and grant funding from emocha Health.	Polly Clayden polly.clayden@i-base.org.uk Polly Clayden has been working as an advocate and activist for over 12 years and co-founded i-Base in April 2000 Conflict of Interest: Has no real or apparent conflicts of interest to report.
Paul L. Domanico, PhD pdomanico@clintonhealthaccess.org Dr. Paul L. Domanico holds a PhD in Chemistry and a Bachelor of Science degree in Pre-Medicine from Penn State University. He received his post-doctoral training in Molecular Biophysics at E.I. du Pont de Nemours and Co. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Lobna Gaayeb, PhD lgaayeb@medicinespatentpool.org Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Rodney JY Ho, PhD, FAAPS, FAAS rodneyho@uw.edu Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. Conflict of Interest: No disclosures.	Jeffrey M. Jacobson, MD jxj573@case.edu Jeffrey M. Jacobson, MD is Professor of Medicine at Case Western Reserve University and Principal Investigator of the Case AIDS Clinical Trials Unit. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Daniel R. Kuritzkes, MD dkuritzkes@bwh.harvard.edu Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. Conflict of Interest: Receives consulting fees from AbbVie, Atea, Decoy, Gilead, GlaxoSmithKline, Janssen, Merck, Moderna, Novartis, Pfizer, Shinogi, ViiV, ViroStatics, and research funding from Gilead, Merck, Viiv.	Imelda Mahaka imahaka@pzat.org Imelda Mahaka is the Executive Director for Pangaea Zimbabwe AIDS Trust (PZAT). She provides strategic direction, overall oversight, coordination, and support for the implementation of PZAT programs. Conflict of Interest:
Jane McKenzie-White, MAS, MSEd jmw@jhmi.edu Ms. McKenzie-White is Managing Director and Senior Program Officer at the Center for Clinical Global Health Education. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Mark Mirochnick, MD Mark.Mirochnick@bmc.org Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. Conflict of Interest: Dr. Mirochnick has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck, ViiV, Gilead, AstraZeneca.
Adeniyi Olangunju, PhD olagunju@liverpool.ac.uk Adeniyi Olagunju is a Tenure Track Fellow in the Department of Pharmacology and Therapeutics at the University of Liverpool. He is a member of the Centre of Excellence for Long-acting Therapeutics (CELT) where he leads the Perinatal Pharmacology Group. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Andrew Owen, PhD, FSB aowen@liverpool.ac.uk Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare
Kimberly Struble, PharmD Kimberly.Struble@fda.hhs.gov Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. Conflict of Interest: None disclosed.	Susan Swindells, MBBS sswindells@unmc.edu Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA. Conflict of Interest: Receives research grants to her institution from ViiV Healthcare.
David Thomas, MD, MPH dthomas@jhmi.edu David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: Has no real or apparent conflicts of interest to report.